Potential in retina treatment offered through stem cell research

Article

A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight.

A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight. This could lead to a potential treatment for retinal diseases that affect around 3000 children in the UK.

Researchers from the UCL Institute of Child Health and UCL Institute of Ophthalmology as well as members of the UCL Centre for Stem Cells and Regenerative Medicine have successfully implanted cells from healthy mice into those with an inherited form of childhood blindness called Leber Congenital Amaurosis (LCA). The implanted cells, which release a gene, Crx, needed to make healthy cone and rod photoreceptors, integrated with the retina to become new cone photoreceptors. This is the first time this has been achieved. However, more studies are required to show if this method could restore sight.

"We have shown for the first time that it is possible to transplant new cone photoreceptors into the mature retina. The newly-developed cones looked as good as new," asserted Dr Jane Sowden, UCL Institute of Child Health, who led the study. "This is an important step forward as cone photoreceptors are essential for reading and colour vision and loss of this type of cell has the biggest impact on sight."

This study is available in Human Molecular Genetics.

For further information on stem cell technology read the upcoming October issue of Ophthalmology Times Europe for "A primer on the use of stem cells in ophthalmology" by Irving Arons.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.